Ciaran O. Reilly

Ciaran O. Reilly

Auto-generated profile, based on publicly available information

Ciaran O. Reilly

Sygnature Discovery Ltd., BioCity, Pennyfoot Street, Nottingham, United Kingdom

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 January 2016 in Medicinal Research Reviews
Verified
Journal Article
Closed access
PDF file
COCiaran O'Reilly
Ciaran O'Reilly
Mohammad DoroudianMohammad Doroudian
Mohammad Doroudian
LMLeona Mawhinney
Leona Mawhinney
SDSeamas C. Donnelly
Seamas C. Donnelly

1 January 2014 in Molecular Medicine
Verified
Journal Article
Open access
LMLeona Mawhinney
Leona Mawhinney
MAMichelle E. Armstrong
Michelle E. Armstrong
COCiaran O’reilly
Ciaran O’reilly
RBRichard Bucala
Richard Bucala
LLLin Leng
Lin Leng
SDSeamas C. Donnelly
Seamas C. Donnelly
The cytokine macrophage migration inhibitory factor (MIF) possesses unique tautomerase enzymatic activity, which contributes to the biological functional activity of MIF. In this study, we investigated the effects of blocking the hydrophobic active site of the tautomerase activity of MIF in the pathogenesis of lung cancer. To address this, we initially established a Lewis lung carcinoma (LLC) murine model in Mif-KO and wild-type (WT) mice and compared tumor growth in a knock-in mouse model expressing a mutant MIF lacking enzymatic activity (Mif (P1G)). Primary tumor growth was significantly attenuated in both Mif-KO and Mif (P1G) mice compared with WT mice. We subsequently undertook a structure-based, virtual screen to identify putative small molecular weight inhibitors specific for the tautomerase enzymatic active site of MIF. From primary and secondary screens, the inhibitor SCD-19 was identified, which significantly attenuated the tautomerase enzymatic activity of MIF in vitro and in biological functional screens. In the LLC murine model, SCD-19, given intraperitoneally at the time of tumor inoculation, was found to significantly reduce primary tumor volume by 90% (p < 0.001) compared with the control treatment. To better replicate the human disease scenario, SCD-19 was given when the tumor was palpable (at d 7 after tumor inoculation) and, again, treatment was found to significantly reduce tumor volume by 81% (p < 0.001) compared with the control treatment. In this report, we identify a novel inhibitor that blocks the hydrophobic pocket of MIF, which houses its specific tautomerase enzymatic activity, and demonstrate that targeting this unique active site significantly attenuates lung cancer growth in in vitro and in vivo systems.

29 August 2011 in Organic Letters
Verified
Journal Article
Closed access
COCiaran O’reilly
Ciaran O’reilly
PMPaul Murphy
Paul Murphy

16 March 2015 in Organic Letters
Verified
Journal Article
Open access
JZJian Zhou
Jian Zhou
MRMairead Reidy
Mairead Reidy
COCiaran O’reilly
Ciaran O’reilly
DJDilip V. Jarikote
Dilip V. Jarikote
Arvind NegiArvind Negi
Arvind Negi
PMPaul V. Murphy
Paul V. Murphy
A build–couple–pair strategy, including double-reductive amination macrocyclization, has been used to generate decorated macrocycles (eannaphanes) with an embedded triazole and monosaccharide. Biological screening led to the identification of an inducer of apoptosis in leukemic cells, which acts at least partially as a 5-HT2 antagonist.

2 August 2017 in The FASEB Journal
Verified
Journal Article
Open access
PDF file
ATAisling Tynan
Aisling Tynan
LMLeona Mawhinney
Leona Mawhinney
MAMichelle E. Armstrong
Michelle E. Armstrong
COCiaran O’rEilly
Ciaran O’rEilly
SKSarah Kennedy
Sarah Kennedy
SDSeamas C. Donnelly
Seamas C. Donnelly
Macrophage migration inhibitory factor (MIF) is a key proinflammatory mediator that we have previously shown to be associated with an aggressive clinical phenotype in cystic fibrosis. It possesses unique tauto‐merase enzymatic activity. However, to date, no human‐derived substrate has been identified that has the capacity to interact with this cytokine’s unique tautomerase activity. This led us to hypothesize that MIF may have the capacity to interact with external substrates. We describe for the first time how Pseudomonas aeruginosa can utilize human recombinant MIF (rMIF) to significantly ( P < 0.01) enhance its endogenous biofilm formation. Our in vivo studies demonstrate that utilizing a small‐molecular‐weight inhibitor targeting MIF’s tautomerase activity (SCD‐19) significantly reduces the inflammatory response in a murine pulmonary chronic P. aeruginosa model. In addition, we show that in in vitro experiments, pretreatment of P. aeruginosa with rMIF is associated with reduced bacterial killing by tobramycin. Our novel findings support the concept of an anti‐MIF strategy that targets this enzymatic activity as a potential future antibacterial therapeutic approach.—Tynan, A., Mawhinney, L., Armstrong, M. E., O’Reilly, C., Kennedy, S., Caraher, E., Jülicher, K., O’Dwyer, D., Maher, L., Schaffer, K., Fabre, A., McKone, E.F., Leng, L., Bucala, R., Bernhagen, J., Cooke, G., Donnelly, S. C. Macrophage migration inhibitory factor enhances Pseudomonas aeruginosa biofilm formation, potentially contributing to cystic fibrosis pathogenesis. FASEB J. 31, 5102–5110 (2017). www.fasebj.org

1 December 2010 in Tetrahedron Letters
Verified
Journal Article
Closed access
DJDilip V. Jarikote
Dilip V. Jarikote
COCiaran O’rEilly
Ciaran O’rEilly
PMPaul V. Murphy
Paul V. Murphy